Quarterly guidance

Quarterly guidance
No specific formal quarterly guidance figures were provided for the fourth quarter.

Annual guidance

Organic sales growth 2026
10% to 10.5%
Adjusted EBITDA 2026
$3.3 billion to $3.4 billion
Net sales growth 2027 framework
High single digits
Adjusted EBITDA growth 2027 framework
Low to mid-single digits

Outlook

Inflation and costs
Diesel, raw materials, and finished good costs are assumed to remain at current elevated levels through 2027.
Pricing
Medline plans to implement a larger than usual price increase early in the first quarter of 2027 to offset a portion of inflationary cost pressures.
Restructuring savings
A newly launched restructuring program is expected to generate $80 million to $90 million in annualized savings, primarily realized in 2027.
Long-term earnings power
Medline continues to expect adjusted EBITDA growth to return to at or above net sales growth in 2028.